Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar (2026-02-04)
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.